Fig. 4From: Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditionsChange from baseline in pre-bronchodilator FEV1 (mL) at Week 24 by comorbidity category. Change from baseline in pre-bronchodilator FEV1 was analyzed using a MMRM analysis. p-interaction < 0.1. AR allergic rhinitis/hay fever; CI confidence interval; FEV1 forced expiratory volume in 1 s; GERD gastroesophageal reflux disease; mepo mepolizumab; MMRM mixed model repeated measuresBack to article page